SG11201708075RA - Treatment of chronic graft versus host disease with syk inhibitors - Google Patents
Treatment of chronic graft versus host disease with syk inhibitorsInfo
- Publication number
- SG11201708075RA SG11201708075RA SG11201708075RA SG11201708075RA SG11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA SG 11201708075R A SG11201708075R A SG 11201708075RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- host disease
- versus host
- graft versus
- chronic graft
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562150691P | 2015-04-21 | 2015-04-21 | |
| PCT/US2016/028303 WO2016172117A1 (en) | 2015-04-21 | 2016-04-19 | Treatment of chronic graft versus host disease with syk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708075RA true SG11201708075RA (en) | 2017-11-29 |
Family
ID=55854820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708075RA SG11201708075RA (en) | 2015-04-21 | 2016-04-19 | Treatment of chronic graft versus host disease with syk inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20160375019A1 (en) |
| EP (1) | EP3285808A1 (en) |
| JP (1) | JP2018513173A (en) |
| KR (1) | KR20170137200A (en) |
| CN (1) | CN107530354A (en) |
| AU (1) | AU2016252387A1 (en) |
| BR (1) | BR112017022323A2 (en) |
| CA (1) | CA2983611A1 (en) |
| EA (1) | EA201791946A1 (en) |
| HK (2) | HK1244453A1 (en) |
| MX (1) | MX2017013496A (en) |
| SG (1) | SG11201708075RA (en) |
| TW (1) | TW201711685A (en) |
| WO (1) | WO2016172117A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104059073B (en) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | Imidazopyrizine Syk Inhibitors |
| KR101717809B1 (en) | 2010-03-11 | 2017-03-17 | 질레드 코네티컷 인코포레이티드 | Imidazopyridines syk inhibitors |
| ES2822285T3 (en) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | SYK inhibitor polymorph |
| AU2014296184B2 (en) | 2013-07-31 | 2017-04-27 | Gilead Sciences, Inc. | Syk inhibitors |
| KR20180002888A (en) | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Methods for treating cancers |
| UY35898A (en) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. |
| BR112016028641A2 (en) | 2014-07-14 | 2017-08-22 | Gilead Sciences Inc | ? method for treating cancer? |
| WO2017106564A1 (en) * | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| US10111882B2 (en) | 2016-09-14 | 2018-10-30 | Gilead Sciences, Inc. | SYK inhibitors |
| CA3051318A1 (en) * | 2017-02-17 | 2018-08-23 | Ose Immunotherapeutics | New uses of anti-sirpg antibodies |
| CA3073871A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | Polymorphs of syk inhibitors |
| CN110272426B (en) | 2018-07-17 | 2022-05-31 | 深圳市塔吉瑞生物医药有限公司 | Alkynyl (hetero) aromatic ring compounds for inhibiting protein kinase activity |
| CN113950479A (en) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | Solid forms of condensed pyrazines as SYK inhibitors |
| CN112939983A (en) * | 2021-02-01 | 2021-06-11 | 暨明医药科技（苏州）有限公司 | Synthesis method of SYK kinase inhibitor Lanraplenib |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037900B2 (en) * | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| CN104744476B (en) | 2008-12-08 | 2017-04-12 | 吉利德康涅狄格公司 | IMIDAZOPYRAZINE Syk INHIBITORS |
| US8450321B2 (en) * | 2008-12-08 | 2013-05-28 | Gilead Connecticut, Inc. | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor |
| ES2822285T3 (en) | 2013-07-30 | 2021-04-30 | Kronos Bio Inc | SYK inhibitor polymorph |
| SI3027171T1 (en) | 2013-07-30 | 2020-08-31 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
| KR20180002888A (en) * | 2013-12-04 | 2018-01-08 | 길리애드 사이언시즈, 인코포레이티드 | Methods for treating cancers |
| UY35898A (en) * | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?. |
| US9290505B2 (en) | 2013-12-23 | 2016-03-22 | Gilead Sciences, Inc. | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors |
-
2016
- 2016-04-19 KR KR1020177033177A patent/KR20170137200A/en not_active Application Discontinuation
- 2016-04-19 MX MX2017013496A patent/MX2017013496A/en unknown
- 2016-04-19 AU AU2016252387A patent/AU2016252387A1/en not_active Abandoned
- 2016-04-19 EP EP16718974.5A patent/EP3285808A1/en not_active Withdrawn
- 2016-04-19 EA EA201791946A patent/EA201791946A1/en unknown
- 2016-04-19 BR BR112017022323-6A patent/BR112017022323A2/en not_active Application Discontinuation
- 2016-04-19 JP JP2017554862A patent/JP2018513173A/en active Pending
- 2016-04-19 CN CN201680023400.1A patent/CN107530354A/en active Pending
- 2016-04-19 SG SG11201708075RA patent/SG11201708075RA/en unknown
- 2016-04-19 WO PCT/US2016/028303 patent/WO2016172117A1/en active Application Filing
- 2016-04-19 US US15/133,041 patent/US20160375019A1/en not_active Abandoned
- 2016-04-19 CA CA2983611A patent/CA2983611A1/en not_active Abandoned
- 2016-04-20 TW TW105112327A patent/TW201711685A/en unknown
-
2018
- 2018-03-23 HK HK18104045.7A patent/HK1244453A1/en unknown
- 2018-07-10 HK HK18108940.4A patent/HK1249054A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201711685A (en) | 2017-04-01 |
| JP2018513173A (en) | 2018-05-24 |
| EP3285808A1 (en) | 2018-02-28 |
| CN107530354A (en) | 2018-01-02 |
| HK1249054A1 (en) | 2018-10-26 |
| KR20170137200A (en) | 2017-12-12 |
| WO2016172117A1 (en) | 2016-10-27 |
| BR112017022323A2 (en) | 2018-07-03 |
| AU2016252387A1 (en) | 2017-10-19 |
| EA201791946A1 (en) | 2018-03-30 |
| MX2017013496A (en) | 2018-02-09 |
| US20160375019A1 (en) | 2016-12-29 |
| CA2983611A1 (en) | 2016-10-27 |
| HK1244453A1 (en) | 2018-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1249054A1 (en) | Treatment of chronic graft versus host disease with syk inhibitors | |
| HK1251409A1 (en) | Methods of treating cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL253945B (en) | Kdm1a inhibitors for the treatment of disease | |
| HK1254349A1 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| EP3122414A4 (en) | Venous disease treatment | |
| FI3851537T3 (en) | Treatment of hyperbilirubinemia | |
| IL278247B (en) | Mct4 inhibitors for treating disease | |
| ZA201706257B (en) | Treatment of wood | |
| EP3134436A4 (en) | Treatment of h-ras-driven tumors | |
| ZA201607740B (en) | Treatment of the complications of chronic liver disease with caspase inhibitors | |
| HK1253238A1 (en) | Gls1 inhibitors for treating disease | |
| HK1258611A1 (en) | Treatment of ascites | |
| PT3164394T (en) | Gls1 inhibitors for treating disease | |
| HK1252245A1 (en) | Nucleotides for the treatment of cancer | |
| EP3134528A4 (en) | Multiple targeted rnai for the treatment of cancers | |
| GB201408297D0 (en) | Treatment of cancer | |
| EP3313403A4 (en) | Treatment of cancer with dnapk inhibitors | |
| GB201417456D0 (en) | Treatment of cancer | |
| EP3854402C0 (en) | Treatment or prevention of graft versus host disease | |
| GB201512723D0 (en) | Treatment of cancer | |
| GB201507928D0 (en) | Treatment of cancer | |
| GB201504617D0 (en) | Treatment of cancer | |
| PT3851537T (en) | Treatment of hyperbilirubinemia | |
| GB201504413D0 (en) | Treatment of disease |